Novocure delivered record quarterly revenue and active patient growth, raised its full-year financial guidance and expanded the commercial reach of Optune Pax with European approval.
Key Investor Takeaways
- Novocure (NASDAQ:NVCR) reported record second-quarter net revenue of $183.6 million, up 16% year over year.
- Global active patients receiving TTFields therapy increased 18% to 5,128 across all indications.
- The company raised its 2026 revenue guidance to $710 million-$725 million and improved its adjusted EBITDA outlook.
- Optune Pax received CE Mark approval for locally advanced pancreatic cancer, with Germany becoming the first European launch market.
- Upcoming FDA and clinical milestones in late 2026 could further expand the commercial opportunity for TTFields therapy.
Why NVCR Stock Is in Focus
Novocure (NASDAQ:NVCR) reported second-quarter net revenue of $183.6 million, representing 16% growth from the prior year, driven primarily by higher global patient adoption of its Tumor Treating Fields (TTFields) therapy.
The company ended the quarter with 5,128 active patients worldwide, an 18% increase year over year. Optune Gio remained the largest contributor with 4,636 active patients, while Optune Lua grew 51% to 207 active patients.
Optune Pax also continued to build momentum following its U.S. launch. The company received 418 prescriptions during the quarter and reported 285 active U.S. patients at June 30.
Commercial expansion continued beyond the United States after Optune Pax received CE Mark approval for the treatment of locally advanced pancreatic cancer. Germany is expected to become the first European market to launch the therapy.
Financial performance also improved. Gross margin increased to 78% from 74% a year earlier, while adjusted EBITDA was positive at $10.8 million. Although Novocure reported a quarterly net loss of $15.7 million, loss per share improved as revenue growth continued to outpace operating expenses.
Why This Matters for Investors
The combination of accelerating patient growth, expanding indications and stronger profitability metrics suggests Novocure is progressing toward a broader commercial platform rather than relying solely on its original glioblastoma franchise.
Management also increased its full-year outlook, raising expected 2026 revenue to $710 million-$725 million from the previous range of $690 million-$710 million. The adjusted EBITDA forecast improved to a range of break-even to $15 million, compared with prior guidance of a loss between $15 million and break-even.
The guidance increase reflects confidence in continued commercial execution across Optune Gio, Optune Lua and Optune Pax. Additional pancreatic cancer launches in Europe could provide another source of revenue growth as reimbursement and market expansion progress.
The company also strengthened its financial position, ending the quarter with $440.6 million in cash, cash equivalents and short-term investments. That liquidity may provide flexibility to support commercial launches, regulatory activities and ongoing clinical development without immediate financing needs.
What to Watch Next
Investors will be watching the rollout of Optune Pax in Europe following the CE Mark approval, beginning with Germany.
Another major catalyst is the expected fourth-quarter 2026 FDA decision on TTFields therapy for brain metastases from non-small cell lung cancer, which could further expand the addressable market.
Completion of enrollment in the Phase 3 KEYNOTE D58 glioblastoma trial before year-end will also be an important milestone as Novocure continues to broaden the clinical evidence supporting its TTFields platform.
Novocure stock price
